ABSTRACT

Introduction In the past 20 years, the increasing burden of heart disease in an ageing population has resulted in cardiac surgery (CS) being offered to more frail and older patients with multiple comorbidities. Frailty and malnutrition are key geriatric syndromes that impact postoperative outcomes, including morbidity, mortality and prolonged hospital length of stay. Enhanced recovery protocols (ERPs), such as prehabilitation, have been associated with a reduction in complications after CS in vulnerable patients. The use of nutritional ERPs may enhance short-term and long-term recovery and mitigate frailty progression while improving patient-reported outcomes.

Methods and analysis This trial is a two-centre, double-blinded, placebo-randomised controlled trial with blinded endpoint assessment and intention-to-treat analysis. One-hundred and fifty CS patients will be randomised to receive either a leucine-rich protein supplement or a placebo with no supplemented protein. Patients will consume their assigned supplement two times per day for approximately 2 weeks pre-procedure, during in-hospital postoperative recovery and for 8 weeks following discharge. The primary outcome will be the Short Physical Performance Battery score. Data collection will occur at four time points including baseline, in-hospital (pre-discharge), 2-month and 6-month time points post-surgery.

Ethics and dissemination The University of Manitoba Biomedical Research Ethics Board (20 March 2018) and the St Boniface Hospital Research Review Committee (28 June 2019) approved the trial protocol for the primary site in Winnipeg, Manitoba, Canada. The second site’s (Montreal, Quebec) ethics has been submitted and pending approval from the Research Ethics and New Technology Development Committee for the Montreal Heart Institute (December 2020). Recruitment for the primary site started February 2020 and the second site will begin January 2021. Data gathered from the PROTein to Enhance outcomes of (pre)frail paTients undergoing Cardiac Surgery Study will be published in peer-reviewed journals and presented at national and international conferences. Knowledge translation strategies will be created to share findings with stakeholders who are positioned to implement evidence-informed change.

Potential study impact Malnutrition and frailty play a crucial role in post-CS recovery. Nutritional ERPs are increasingly being recognised as a clinically relevant aspect of perioperative care. As such, this trial is to determine if leucine-rich protein supplementation at key intervals can mitigate frailty progression and facilitate enhanced postoperative recovery.

Trial registration number ClinicalTrials.gov Registry (NCT0438294).

INTRODUCTION

By 2031, 25% of Canadians will be older than 65 years. By extension, it is expected that greater numbers of frail (defined as a cumulative decline in multiple physiological systems resulting in a vulnerability to stressor events) older adult individuals will be referred for a cardiac surgery procedure. While frailty is not necessarily synonymous with age, it is more prevalent among an older adult population. More specifically, in the last two decades, the increasing burden of heart disease has resulted in cardiac surgery being offered to older and more frail patients. Previous studies have demonstrated that patients with higher levels of frailty prevalence, ranging from 20% to 53%, depending on the evaluation tool.
used, typically experience higher rates of postoperative morbidity, mortality and prolonged hospital length of stay with associated increased costs to the Canadian healthcare system.\textsuperscript{7–9,41} It has been previously identified that approximately 50% of older adults undergoing cardiac surgery are frail, resulting in a population who are at a higher risk for poor outcomes versus non-cardiac surgery patients.\textsuperscript{12,13} Furthermore, pre-frail (defined as a transitional physiological state between robustness and frailty, characterised by intermediate accumulation of physiological dysfunction, resulting in a minimal decline in physiological reserve and functional capacity, supported by a Clinical Frailty Scale (CFS) score equal to 3\textsuperscript{14–16}) cardiac surgery patients are at an increased risk of adverse events such as increased duration of mechanical ventilation, morbidity and hospital stay,\textsuperscript{16,17} as well as postoperative frailty progression that ultimately results in functional disability and worse health-related quality of life (HRQoL).\textsuperscript{18,19}

Outcomes associated with frail cardiac surgery patients are impacted further by malnutrition (defined as an unintentional, nutritional intake imbalance (not necessarily a decreased intake)), which is evident in 20% of the patients presenting for cardiac surgery.\textsuperscript{20,21} Chronic malnutrition which results from age-related physiological decline (ie, decreased mobility, sensory functions (olfaction and taste) and cognition), physiological challenges (ie, increased dependency and loneliness) and chronic illness (ie, cardiovascular, polypharmacy)\textsuperscript{22,23} in combination with perioperative starvation, which is the typical perioperative fasting, inflammatory and regenerative processes that induce an exponential nutritional demand resulting in an additional demand–supply imbalance (ie, a state of metabolic stress) can cause a further decline in health status and poor recovery to baseline functional capacity in already frail patients.

Malnutrition and frailty have shared risk factors with overlapping clinical presentation that exacerbate each syndrome.\textsuperscript{7,44–47} The previous standard preoperative protocol requires preoperative fasting for 6–8 hours (may extend to 8–12 hours). Further, a delay (mean of 2 days) in initiating postoperative nutritional support as well as an inadequacy of caloric intake (approximately 70% less than the recommended intake) has often been reported in cardiac surgery patients.\textsuperscript{28,29} This perioperative underfeeding compound the pre-existing chronic malnutrition in frail older patients undergoing cardiac surgery. Malnutrition can manifest into a catastrophic fat-free muscle mass decline, that intensifies ‘senile sarcopenia’ (defined as the typical age-related involuntary muscle and organ degradation; typically, 1%–2% per year after 30 years)\textsuperscript{30–32} This altogether results in an exponential loss of lean muscle mass (sarcopenia) and muscle function (dynamenias) with ageing.\textsuperscript{33–35} Importantly, even a minimal (10%) loss of fat-free muscle mass was found to be associated with a progressive functional decline, increased mortality and increased utilisation of healthcare services (including premature institutionalisation) among community-dwelling older adults.\textsuperscript{35} Furthermore, the malnutrition-accelerated decline in lean muscle mass and muscle function are consistent features of frailty (coined as the biological substrate of frailty exacerbation)\textsuperscript{36}. The frail–malnourished patients cannot mobilise enough amino acids to commensurate with the 400% increased demand required to synthesise proteins for wound healing, immune function and acute-phase reactants.\textsuperscript{37} To compound this issue, the metabolic and immune response to injury induces insulin resistance\textsuperscript{38} further aggravating a caloric deficient state. Ultimately, this perioperative demand–supply imbalance results in an extensive insult to a reserve-deficient physiological system (as in a typical frail patient), disproportionately declining the health status and limiting a patient’s recovery to baseline functional capacity.

Providing protein–caloric supplementation preoperatively, postoperatively and post-hospital discharge is recommended by many consensus guidelines\textsuperscript{39} including: enhanced recovery protocols (ERPs),\textsuperscript{40} The European Society for Clinical Nutrition and Metabolism\textsuperscript{41} and the Canadian Nutritional Support Clinical practice guidelines.\textsuperscript{42} Nutritional supplementation can be viewed as a potentially modifiable factor that can alleviate the preoperative frailty–chronic malnutrition associated with vulnerability. Cardiac surgery patients, in addition to their cardiac disease and associated comorbidities, experience higher levels of frailty and malnutrition versus other non-cardiac surgery patients.\textsuperscript{43–45} There is a significant knowledge gap regarding the efficacy of nutritional prehabilitation in preserving functional capacity (ie, mitigating frailty progression) and promoting enhanced recovery, among (pre)frail older adults undergoing cardiac surgery.

Enhanced recovery protocols, such as prehabilitation, have been associated with a reduction in overall complications and length of stay of up to 50% in vulnerable patients when compared with conventional perioperative patients in non-cardiac surgery populations.\textsuperscript{46–48} Early feasibility studies have shown promise with ERPs in cardiac surgery as well, however, require additional rigorous inquiry. Specifically, the impact of a nutritional supplementation ERP on mitigating long-term frailty progression and improving patient-reported outcomes (patient valued survivorship and recovery) in an increasingly ageing cardiac surgery patient population has been largely understudied. In Canada, when a patient requires elective cardiac surgery, they are placed on a ‘waiting list’ for as long as 3–4 months. At present, there is no formal process for engaging these patients to enhance their health during this waiting period, which represents a significant opportunity to optimise a (pre)frail older adult patient’s clinical condition prior to surgery. Additionally, the consideration of longer term (not just in-hospital) HRQoL is vitally important to the patient–caregiver unit. As a result, it is becoming critically important for the healthcare system to develop strategies to improve clinical outcomes in this high-risk patient population.

The PROTein to Enhance outComes of (pre)frail paTients undergoing Cardiac Surgery (the PROTECT-CS
Study) was developed as a practical and sustainable, new perioperative care pathway, informed by patient–
caregiver values, to enhance short-term and long-term
recovery of vulnerable cardiac surgery patients.

The primary objectives of the trial are:

1. To determine if a leucine-rich protein supplementation,
   consumed two times per day for a minimum of
   7 days pre-procedure for elective patients (minimum of
   2 days for non-emergent inpatients), two times per
day during in-hospital postoperative recovery and
two times per day for 8 weeks after the patient is
discharged home can reduce perioperative functional de-
cline among (pre)frail older cardiac surgery patients.

2. To determine if a perioperative leucine-rich protein
   supplementation will enhance short-term and longer
term patient-reported outcomes.

We hypothesise that the preoperative and postoperative
supplementation of leucine-rich-formulated beverages to
a patient’s habitual diet will support the physiological
processes to counter the impact of cardiac surgery-related
stressors to reduce the postoperative functional decline.
We also hypothesise that nutrition supplementation using
a leucine-rich protein supplementation will facilitate post-
operative recovery and improve self-reported HRQoL in
(pre)frail cardiac surgery patients.

POTENTIAL IMPACT OF STUDY

To date, no high-quality study has prospectively exam-
ined the impact of perioperative nutrition supplemen-
tation in the higher risk, (pre)frail older adult undergoing
cardiac surgery. The impact of the PROTECT-CS Study
may provide a much-needed framework to direct future
surgical practice and to inform ERP guidelines in the
cardiac surgery patient. The PROTECT-CS Study is highly
relevant and aims to improve the patient-centred and
patient-driven perioperative approach for the optimis-
ation of the (pre)frail older adult undergoing cardiac
surgery. We endeavour to ensure patients do not just
‘survive but thrive’ after their heart surgery.

METHODS AND ANALYSIS

The PROTECT-CS Study is a patient/researcher collabor-
ative study, involving two Canadian centres. The study is
a double-blinded, placebo randomised controlled trial
(RCT) with blinded endpoint assessment and intention-
to-treat analysis. Randomisation of the placebo and
supplement is stratified by site and sex. Additionally, a
third party will be randomising the patients for this study
to ensure double blinding. At present, there is no formal
process for engaging patients undergoing cardiac surgery
to enhance their health during their waiting period. There
is a significant knowledge gap regarding the efficacy of
nutritional supplementation in preserving functional
capacity and promoting enhanced recovery, among (pre)
frail older adults undergoing cardiac surgery. Improved
perioperative processes that address frailty and proper
nutrition are of significant value to the patient–caregiver
unit. This study is funded by the Heart and Stroke Foun-
dation of Canada. We have used the Standard Protocol
Items: Recommendations for Interventions Trials guide-
lines, the Sex and Gender Equity in Research guidelines
and the Consolidated Standards of Reporting Trials
guidelines in reporting this clinical trial. A description of
this clinical trial is available on http://ClinicalTrials.gov.

PATIENT AND PUBLIC INVOLVEMENT

Patient engagement in research involves meaningful and
active collaborations between patients and researchers
throughout the different phases of a research project,
including planning, study design, data collection, data anal-
ysis and knowledge translation (KT).48 We have recruited 10
patients and caregivers to collaborate as research partners
on this study through membership on an advisory panel.
Panel members were recruited from a database of previous
cardiac surgery patients who agreed to be contacted for
future research. We selectively chose panel members to
reflect key demographic characteristics of our study’s
target population. We anticipate that we will collaborate
with the advisory panel across the study’s entire research
cycle—from study planning through to the end of study KT
(3 years)—predominantly through face-to-face meetings.

Figure 1 outlines the different areas that the advisory panel
may contribute to the study. These include providing input
on study implementation refinement and procedures (eg,
recruitment methods, approaches to maximise adherence
to supplement-intake protocols, use of accessible language
in recruitment and study materials, and usability of tech-
nology), relevance of outcomes to patient concerns, data
analysis (eg, interpretation and contextualisation of find-
ings) and KT (eg, alternate dissemination methods, use of
accessible language).49

STUDY SETTING

The PROTECT-CS trial will be conducted and recruited in
two sites across Canada: (1) Winnipeg, Manitoba, St
Boniface Hospital; (2) Montreal, Quebec, Jewish General
Hospital.

RECRUITMENT

This study will recruit 150 patients over a 24-month
recruitment period, starting January 2020, between both
sites (ie, four per month for the primary site and two per
month for the second site). We expect a total recruitment
rate of approximately 20%–25% of potentially eligible
patients based on previous research50 (figure 2).

ELIGIBILITY CRITERIA

Screening

Initial screening for the study will include the CFS, the
Short Performance Physical Battery (SPPB) and the Short
Form-36 Physical Function (SF-36-PF) survey to measure frailty status in potential study patients. We have defined a CFS of greater than or equal to 3 (classified as ‘managing well’), but not 7 (severely frail) or higher as an initial indicator of frailty for the purposes of our study’s inclusion criteria. An SPPB score of less than or equal to 9 or a score of ≤60 on the SF-36-PF questionnaire for suitable participation. If the screening criteria are met, the research team will obtain signed consent, administer all baseline assessments and randomly allocate each patient to the appropriate research group (ie, protein or placebo). Patients who do not meet the frailty inclusion criteria are excluded based on specific criteria or refuse to be randomised into the main study will be given the opportunity to participate in the registry component of the study (figure 3).

OUTCOMES AND INSTRUMENTATION

The primary outcome is a change in the SPPB score and the SF-36-PF score at 2 (short) and 6 (longer term) months compared with baseline. Due to the global pandemic (COVID-19), research initiatives that collected data through in-person meetings were suspended on two occasions (March 2020–August 2020, and November 2020—to be discussed (TBD)). As a result, we developed an alternative primary outcome (ie, SF-36-PF) to implement for the trial in order to accommodate the institutional directive to transition research to use remote/virtual data collection strategies. The SF-36-PF is an optimal outcome measure appropriate for our study cohort, as it is correlated with the SPPB (r=0.5–0.6) and is a surrogate measure of physical function. Secondary outcomes are adherence to supplementation, fat-free muscle mass (measured by a portable bioimpedance device); HRQoL measured by the EQ-5D-3L, EQ-Visual Analogue Scale (EQ-VAS)52 and the Older American Resource Scale (OARS): Activities of Daily Living (ADL) and Instrumental ADL (IADL) questionnaire53; mood as measured by the Patient Health Questionnaire-9 (PHQ-9)54; current nutrition as measured by the Mini Nutrition Assessment (MNA) tool55; anxiety as measured by the Cardiac Anxiety Questionnaire (CAQ)56; self-reported physical activity, exhaustion and nutrition as assessed by the Modified Fried Questionnaire26; physical activity accumulation as measured by actical accelerometers, aerobic fitness as measured by the 6Min Walk Test (6MWDT); and a composite safety endpoint of all-cause mortality, injurious fall, acute kidney injury or readmission.
Box 1  Inclusion and exclusion criteria for the PROTECT-CS trial

Inclusion criteria
- Patients aged 60 years or older, undergoing elective or non-emergent isolated CABG, aortic valve repair or replacement for moderate aortic stenosis or severe regurgitation, mitral valve repair or replacement for moderate mitral stenosis or severe regurgitation, or combined CABG/valve procedures.
- Patient with a Clinical Frailty Scale (CFS) from 3 (managing well) to 6 (moderately frail).
- Patients with an estimated wait time of approximately 7 days or longer for elective surgery or 2 days or longer for non-emergent surgery.

Exclusion criteria
- Decompensated or non-ambulatory class IV symptoms of angina, dyspnoea and claudication.
- Patients with a CFS of 7 or greater (severely frail to terminally ill); this will exclude less than 1% of the population on the elective cardiac surgery waitlist.
- Creatinine clearance <30 mL/min/1.73 m².
- Cirrhosis (Child-Pugh class B or greater).
- Allergy to milk proteins or other ingredients in the supplement.
- Inability to safely ingest beverages by mouth.
- Mild-to-severe cognitive impairment (ie, Montreal Cognitive Assessment <16).
- An inability to speak/read in English or French.
- Emergent patients or non-emergent patients going for surgery within 48 hours of admission to hospital.

Inclusion and exclusion criteria for the PROTECT-CS trial

Inclusion criteria
- Patients aged 60 years or older, undergoing elective or non-emergent isolated CABG, aortic valve repair or replacement for moderate aortic stenosis or severe regurgitation, mitral valve repair or replacement for moderate mitral stenosis or severe regurgitation, or combined CABG/valve procedures.
- Patient with a Clinical Frailty Scale (CFS) from 3 (managing well) to 6 (moderately frail).
- Patients with an estimated wait time of approximately 7 days or longer for elective surgery or 2 days or longer for non-emergent surgery.

Exclusion criteria
- Decompensated or non-ambulatory class IV symptoms of angina, dyspnoea and claudication.
- Patients with a CFS of 7 or greater (severely frail to terminally ill); this will exclude less than 1% of the population on the elective cardiac surgery waitlist.
- Creatinine clearance <30 mL/min/1.73 m².
- Cirrhosis (Child-Pugh class B or greater).
- Allergy to milk proteins or other ingredients in the supplement.
- Inability to safely ingest beverages by mouth.
- Mild-to-severe cognitive impairment (ie, Montreal Cognitive Assessment <16).
- An inability to speak/read in English or French.
- Emergent patients or non-emergent patients going for surgery within 48 hours of admission to hospital.

CABG, coronary artery bypass grafting; PROTECT-CS, PROTein to Enhance outComes of (pre)frail paTients undergoing Cardiac Surgery.

Figure 3  PROTECT-CS screening and allocation plan. CFS, Clinical Frailty Scale; PROTECT-CS, PROTein to Enhance outComes of (pre)frail paTients undergoing Cardiac Surgery; SPPB, Short Performance Physical Battery.

for related events at 2 months provided by medical records. The primary and secondary outcomes will be assessed at baseline prior to cardiac surgery procedure and reassessed at 2 and 6 months post-hospital discharge. Additionally, the SPPB, SF-36-PF, fat-free muscle mass (assessed by bioelectrical impedance analysis (BIA)) and the MNA, and an assessment of nausea and vomiting symptoms will be reassessed while in-hospital prior to discharge if appropriate. It should be noted, the portable BIA device uses segmental multifrequency technology to measure muscle mass with an accuracy comparable with dual X-ray absorptiometry; and while the accuracy is inferior to that of CT and MRI, it is endorsed by consensus guidelines as a ‘good portable alternative that is inexpensive, easy to use, and readily reproducible’.

BLINDING

Patients will be blinded to the treatment group allocation, as well as the research staff who will assess the fat-free muscle mass, the SPPB and other endpoints at each time point to avoid ascertainment bias.

STUDY INTERVENTION

Study participants

All patients consenting to the study will be randomly allocated to either a protein or placebo group and will undergo the standard preoperative evaluation for suitability and planning for their cardiac surgery procedures. Patients will then be placed on the surgical waitlist. At the time of their cardiac surgery, both the placebo and protein group participants will ingest a carbohydrate beverage, PREcovery, (ie, 50 g of complex carbohydrates; aka CHO loading) 2–3 hours before surgery. The carbohydrate beverage consumed before surgery reduces insulin resistance and tissue glycosylation, improves postoperative glucose control, reduces nausea and vomiting, and also enhances the return of gastrointestinal function post-surgery.

Protein group

Patients randomised to the protein group will receive a leucine-rich protein supplement derived and provided by Enhanced Medical Nutrition (https://enmhealth.com/). The product contains 25 g protein and 3 g leucine per serving (total caloric value: 160 Kcal) to be reconstituted and consumed two times per day for a minimum of 2 weeks pre-procedure, two times per day during postoperative in-hospital recovery (~5–10 days) and two times per day for 8 weeks after the patient is discharged home. The supplement will be consumed approximately 1–2 hours after the morning meal and also 1–2 hours after lunch or before bedtime so as to supplement rather than replace meals. The protein supplement (ISOLution) is formulated to minimise appetite suppression. A research assistant, who is blinded to group allocation, will provide the patient’s supply of supplements at the time of study consent (supplementation prior to cardiac surgery) and after discharge from the hospital (supplementation after
cardiac surgery). In-hospital supplementation will be provided to the patient directly from research staff on a daily basis until discharged home. Phone calls will also be made to participants once per week to ensure compliance. Patients will be encouraged to perform light-to-moderate-intensity aerobic activity up to 30 min, 5 days per week as tolerated based on the 2016 edition of ‘Living well with heart disease’, published by the Heart and Stroke Foundation of Canada.60 This brochure outlines practical tips to safely begin a walking programme and gradually increase walking time to meet the goal of 150 min per week.

**Placebo group**

Enrolled patients allocated to the placebo group will receive the same supplementation schedule followed by the protein group, as well as compliance verification; however, they will receive a placebo product with no supplemented protein (no additional nutritional benefit). This placebo product derived and provided by the Enhanced Medical Nutrition (https://emnhealth.com/) will look exactly like the protein-rich supplement. A research assistant, who is blinded to group allocation, will provide the patient’s supply of supplements at the time of study consent (supplementation prior to cardiac surgery) and after discharge from the hospital (supplementation after cardiac surgery). In-hospital supplementation will be provided to the patient directly from research staff on a daily basis until discharged home. Phone calls will also be made to participants once per week to ensure compliance. Additionally, patients will be encouraged to perform light-to-moderate-intensity aerobic activity up to 30 min, 5 days per week as tolerated based on the 2016 edition of ‘Living well with heart disease’, published by the Heart and Stroke Foundation of Canada.60 This brochure outlines practical tips to safely begin a walking programme and gradually increase walking time to meet the goal of 150 min per week.

**Registry group**

Patients undergoing cardiac surgery who want to participate in the research but refuse to be randomised into the protein group or the placebo group, or those who want to participate in the research but are excluded based on specific study criteria, will be invited to participate in a registry group that will be followed for the purpose of documenting the effects of standard care. Registry participants will not be required to consume study supplements or CHO prior to surgery. Participants will be asked to complete basic demographic and quality of life questionnaires during their consent process and at 2 and 6 months after their cardiac surgery. Additionally, prior to their discharge from the hospital after their cardiac surgery, they will be asked about their postoperative experience specifically related to nausea, vomiting and nutrition while in hospital.

**DATA COLLECTION AND MANAGEMENT**

Participants will meet with the research staff for data collection at four separate points. This will include after consenting to their surgical procedure (baseline pre-surgery), during the in-hospital stay (postoperatively prior to discharge), and at the 2-month and 6-month time point post-surgery. The SPPB and SF-36-PF will be assessed to determine frailty status change at discharge, 2-month and 6-month post-surgery. The 6MWT, hand grip assessment and Fried Questionnaires will also be used to assess frailty in study participants at the above time points. Additionally, nutrition will be assessed by the MNA questionnaire at baseline, in-hospital (postoperatively prior to discharge), at 2-month and 6-month post-surgery. During the in-hospital research visit, all participants’ nausea and vomiting symptoms will be assessed by research staff. Objective measurements of fat-free muscle mass will be obtained by using a BIA device which will be assessed at baseline, in-hospital (postoperatively prior to discharge), and during 2-month and 6-month post-surgery follow-up visits. Physical activity, sedentary behaviour and compliance to physical activity recommendations will be assessed by an accelerometer that participants will wear for a period of 7 days at baseline and at 2-month and 6-month post-surgery follow-up appointments. As COVID-19-related restrictions continue to persist, the potential of in-person visits is diminished based on institutional protocols. Therefore, assessment of physical parameters may not be possible for each research appointment. However, survey administration will continue for all research time points.

The EQ-5D-3L, the EQ-VAS, and the OARS ADL and IADL will assess HRQoL at baseline, 2-month and 6-month post-surgery time points. The PHQ-9 and the CAQ will be administered at baseline, 2-month and 6-month post-surgery time points.

Sex and gender data will be collected at baseline and analysed to identify relationships as they occur within this cohort of cardiac surgery patients. We will capture this information through questionnaires as part of the survey package presented to research participants. Specifically, participants will be asked: (1) what is your assigned sex? (forced choice: male, female or intersex) and (2) what is your gender identity? (man, woman or please specify open-ended response)). It has been previously published that gender and sex differences are a consideration regarding risk for and outcomes of cardiovascular disease.61

**Sample size**

Based on a previously observed distribution of SPPB scores in our elective cardiac surgery population, we expect this effect size will be approximately equivalent to either a 1-point change in the SPPB score or a 10-point change in SF-36-PF score. This magnitude of change in SPPB score is associated with a ‘substantial’ improvement in mobility and quality of life,27 and survival.62 Furthermore, the scale of change for the SF-36-PF is sensitive to detect even a small and clinically meaningful change in physical functioning.63 Due to the global pandemic


---

Open access
(COVID-19), research initiatives that collected data through in-person meetings were suspended on two occasions (March 2020–August 2020, and November 2020—TBD). As a result, we developed an alternative primary outcome (ie, SF-36-PF) to implement for the trial in order to accommodate the institutional directive to transition research to use remote/virtual data collection strategies. The SF-36-PF is an optimal outcome measure appropriate for our study cohort, as it is correlated with the SPPB (r=0.5–0.6) and is a surrogate measure of physical function. A sample size of 150 patients (75 in each group) will allow for an overall drop-out rate of 15% (n=22) while maintaining a moderate Cohen’s effect size (0.5) to detect the difference in change experienced between the two experimental groups at each follow-up time point with a two-tailed alpha of 0.05 and a power of 80% for the continuous primary outcomes. G*Power V.3.1 was used to calculate sample size for this study.

Statistical methods
The primary analysis for this project will be intention-to-treat. A secondary a priori per-protocol analysis will be performed to assess the efficacy of the protein-rich nutritional supplement on the primary and secondary outcomes. Continuous outcome variables measured at multiple time points will be analysed using a repeated measure analysis of covariance (ANCOVA) considering site and sex as fixed effects. Additional covariates such as age, comorbidities and baseline cardiac function may be considered in the ANCOVA analysis if other imbalances remain following randomisation. Post hoc analysis that applies a Bonferroni correction to control the familywise error rate will be performed to identify how the primary and secondary outcomes change at each time point. Categorical outcome variables will be compared using a Χ² test or Fisher’s exact test where appropriate. A sex-based and gender-based analysis will be performed by either stratifying the analysis or by including sex and gender as independent factors in the main analysis. Standardised mean differences will be calculated for several important perioperative characteristics to assess the covariate balance between study groups. Inverse probability of treatment weighting or multivariable regression techniques may also be considered if the ANCOVA assumptions are violated. The study biostatistician, who is experienced in RCT methodology, will oversee all statistical analyses.

Data monitoring
A research coordinator will work out of the I H Asper Clinical Research Institute at the St Boniface Hospital/Research Centre, where the principal investigator and co-investigator are primarily appointed. Data management services, statistical and methodological support are to be housed within the Cardiac Sciences Program at the St Boniface Hospital. The research coordinator will assume responsibility for the data handling. The REDCap platform, housed on a virtual private network at the University of Manitoba, has been used for data collection to ensure safe storage of electronic data for both study sites.

ETHICS AND DISSEMINATION
Informed consent
Patients will first consent to their surgical procedure before being considered for study participation. The patient will be approached and informed about the trial by the research assistant and provided with a copy of the patient information and consent form. Patients will be given adequate amount of time to consider their participation in the trial and will be given an opportunity to ask questions if needed. If the patient decides to participate in the study, they will be asked to provide written consent. All participants are free to withdraw from the study at any time, without any prejudice to future medical treatment.

Trial monitoring and safety
The study collaborators are responsible for ensuring proposed milestones and deadlines are met. They are also responsible for study design, management, ethical conduct, analysis and dissemination of results. Safety data, including new hospitalisation, worsening heart symptoms and other adverse events will be captured and reportable to the study Data and Safety Monitoring Board (DSMB) as they occur. The DSMB is an independent group of experts that advises study investigators. They are responsible for a periodical evaluation of the study data (ie, every 6 months) for participant safety and study conduct, in addition to making recommendations concerning the modification and/or termination of the trial.

Dissemination
Results will be distributed to an interdisciplinary team of cardiologists, cardiac surgeons, geriatricians, nurses, dieticians, rehabilitation providers, policymakers and patients by way of printed and electronic educational materials as well as oral presentation at regional meetings. Furthermore, we have formulated an integrated KT (iKT) team with a dedicated patient panel. Our iKT strategy will seek to adapt the intervention to local resources and expertise by including clinicians, dieticians and patient panels to develop a clinical pathway for the institution of treatment strategies with a mean of evaluation of effectiveness using the Plan–Do–Study–Act cycle (a framework for developing, testing and implementing changes leading to improvement). We will validate our results in a larger multicentre trial leveraging ERAS Cardiac Surgery Society and CANCARE Society participating sites. In addition, we will organise focus group sessions with the patient–caregiver unit and our industry partner to seek their input to further refine and improve the leucine-rich protein–caloric supplement. In doing so, patients can transform the research process from one directed by investigators to one driven and informed by the needs of patients and their caregivers. Patient engagement is recognised as a necessary approach to the building of a
sustainable and equitable healthcare system and to improve health outcomes. 66

Author affiliations
1Faculty of Kinesiology and Recreation Management, University of Manitoba, Winnipeg, Manitoba, Canada
2Health, Leisure and Human Performance Research Institute, University of Manitoba, Winnipeg, Manitoba, Canada
3Institute of Cardiovascular Sciences, St. Boniface General Hospital Albrechtsson Research Centre, Winnipeg, Manitoba, Canada
4Cardiac Science Manitoba, St. Boniface Hospital, Winnipeg, Manitoba, Canada
5Department of Medicine, McGill University, Montreal, Quebec, Canada
6College of Nursing, University of Manitoba, Winnipeg, Manitoba, Canada
7Department of Family Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
8Department of Physiotherapy, Dalhousie University, Halifax, Nova Scotia, Canada
9Department of Surgery, University of Manitoba, Winnipeg, Manitoba, Canada

Twitter Rakesh C Arora @TheRakeshArora

Acknowledgements This research study acknowledges the support of the cardiac surgery healthcare staff and research offices at the St Boniface Hospital. We also wish to acknowledge and thank our patient collaborators for their contributions to the design and direction of this study. By using patient collaboration, we were able to design a study supported by patients for patients. The patient collaborative efforts were invaluable to our research group.

Contributors RCA and TD are co-author authors. AVR and DEK were involved in the manuscript preparation. CH, DEK, JA, ASHS, AC, DSK and MD were involved in the conception of the study design, AVR, CH, DEK, JA, ASHS, AC, DSK and MD were involved in the manuscript revisions.

Funding This work was supported by the Heart and Stroke Foundation of Canada, grant number G-19-0024269. RCA has received an unrestricted educational grant from Pfizer Canada and received honoraria from Abbott Nutrition for work unrelated to this manuscript.

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open-access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the license is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Alexandra V Rose http://orcid.org/0000-0003-4600-2848
Anna Chudyk http://orcid.org/0000-0001-8476-2093

REFERENCES
60 Heart and stroke Foundation of Canada. *Living well with heart disease. Toronto: heart and Stroke, 2016.*